Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Qiagen NV    QGEN   NL0000240000

QIAGEN NV (QGEN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

QIAGEN NV : Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2010 Financial Results Call Set for August 10

08/03/2010 | 08:05am US/Eastern

VENLO, The Netherlands, Aug. 3 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN) today announced the Webcast of its second quarter 2010 financial results call. The Webcast will take place at 9:30 a.m. EDT on Tuesday, August 10, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.


                    Webcast of QIAGEN's second quarter 2010 financial
    What:            results call

    When:           9:30 a.m. EDT on August 10

                    The Webcast is accessible at www.qiagen.com/goto/
    Where:           ConferenceCall

    How:            Log on to the Web at the address above

                    The corresponding presentation slides will be
                    available for download in the investor relations
                    section of QIAGEN's Web site at www.qiagen.com/
                    goto/ConferenceCall.

                    Andreas Marathovouniotis, Russo Partners, (212)
    Contact:        845-4235

QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer.

QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com.

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from http://www.real.com/products/player/index.html, or The Windows Media Player, downloadable free from www.microsoft.com and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to prnwebcast@multivu.com.)

SOURCE QIAGEN N.V.

React to this article
Latest news on QIAGEN NV
02/03 QIAGEN NV : Investigator human identity testing products meet new ISO standard
02/02 QIAGEN NV : New agreements underscore QIAGEN’s leadership in bioinformatic..
02/02 QIAGEN NV : Reports Results for Fourth Quarter and Full-Year 2015
02/02 QIAGEN NV : New Agreements Underscore QIAGEN's Leadership in Bioinformatics
01/26 QIAGEN NV : to Supply QuantiFERON-TB Tests to Ease Tuberculin Shortage
01/19 QIAGEN NV : N.V. : to Report Fourth Quarter and Full-year 2015 Results
01/10 QIAGEN NV : Ad-hoc Announcement according to § 15 WpHG
01/10 QIAGEN NV : Announces Preliminary Results for Full-Year 2015 and Provides 2016 O..
2015 QIAGEN NV : Solving a crime – the real-life way
2015 QIAGEN NV : Solving a crime – the real-life way